Bank of America Corp DE boosted its position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 22.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 166,775 shares of the company's stock after purchasing an additional 30,789 shares during the quarter. Bank of America Corp DE owned approximately 0.44% of Disc Medicine worth $10,664,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Disc Medicine by 22.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company's stock worth $756,000 after acquiring an additional 2,807 shares in the last quarter. Millennium Management LLC increased its position in shares of Disc Medicine by 1,277.1% during the first quarter. Millennium Management LLC now owns 108,499 shares of the company's stock worth $5,386,000 after purchasing an additional 100,620 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Disc Medicine by 3.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company's stock valued at $4,793,000 after purchasing an additional 3,454 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Disc Medicine by 18.0% during the 2nd quarter. Legal & General Group Plc now owns 24,097 shares of the company's stock valued at $1,276,000 after purchasing an additional 3,682 shares during the last quarter. Finally, Invesco Ltd. boosted its position in shares of Disc Medicine by 21.6% in the 2nd quarter. Invesco Ltd. now owns 16,817 shares of the company's stock worth $891,000 after purchasing an additional 2,983 shares in the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Disc Medicine news, insider Rahul Khara sold 7,500 shares of the company's stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $70.22, for a total value of $526,650.00. Following the sale, the insider directly owned 52,173 shares of the company's stock, valued at approximately $3,663,588.06. This represents a 12.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John D. Quisel sold 34,000 shares of the stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $70.21, for a total value of $2,387,140.00. Following the sale, the chief executive officer directly owned 226,064 shares in the company, valued at $15,871,953.44. This represents a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 144,516 shares of company stock worth $10,675,929. 3.76% of the stock is owned by company insiders.
Disc Medicine Price Performance
Disc Medicine stock opened at $79.81 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The business's 50-day simple moving average is $75.84 and its two-hundred day simple moving average is $69.91. The company has a market cap of $3.06 billion, a PE ratio of -12.13 and a beta of 1.00. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50.
Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating analysts' consensus estimates of ($1.71) by $0.17. Equities analysts anticipate that Disc Medicine, Inc. will post -6.61 EPS for the current year.
Wall Street Analyst Weigh In
IRON has been the topic of several recent analyst reports. Wall Street Zen raised Disc Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, August 1st. Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a report on Friday, July 17th. Morgan Stanley restated an "overweight" rating and set a $90.00 price target on shares of Disc Medicine in a research note on Monday, August 17th. Wedbush restated an "outperform" rating and set a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Finally, HC Wainwright increased their price objective on shares of Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $106.50.
Read Our Latest Report on Disc Medicine
About Disc Medicine
(
Free Report)
Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Disc Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.
While Disc Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
